Trial Profile

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Cisplatin; Docetaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms CHIO3 Trial

Most Recent Events

10 Sep 2024 Results evaluating combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery presented at the 25th World Conference on Lung Cancer.
06 Feb 2024 Planned End Date changed from 1 Sep 2024 to 1 Jun 2026.
06 Feb 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com